

REVIEW PAPER

## Pluronic as nano-carrier platform for drug delivery systems

Abbas Rahdar<sup>1\*</sup>, Susan kazemi<sup>2</sup>, Faezeh Askari<sup>3</sup>

<sup>1</sup> Department of Physics, University of Zabol, Zabol, Iran

<sup>2</sup> M.Sc. of Polymer and Materials Chemistry, Faculty of Chemistry and Petroleum Sciences, Shahid Beheshti University, Tehran, Iran

<sup>2</sup> M.Sc. of Nano-chemistry, Kharazmi University, Tehran, Iran

### ARTICLE INFO

#### Article History:

Received 5 June 2018

Accepted 22 July 2018

Published 15 August 2018

#### Keywords:

ATP

Drug Delivery

Nano Carrier

Pluronic

### ABSTRACT

A usual method to build a nano-drug delivery system is incorporating the drug within the nano-carrier to high solubility, improved circulation time, and metabolic stability. However, recent studies indicate that the polymeric nanomaterials can be applied more than the inert carrier functions based on the biological response modifiers. Tri-block copolymers of Pluronic as one of these polymeric materials that they cause different functional alterations within cells. The key characteristic related to the biological activity of Pluronics is their ability to incorporate drug into membranes followed by subsequent translocation into the cells and then affecting the different cellular functions such as ATP synthesis, mitochondrial respiration, activity of drug efflux transporters, gene expression, apoptotic signal transduction and so on. As a result, Pluronics cause effective sensitization to the different anticancer agents based on the multidrug resistant (MDR) and resulting increase in the drug transport across the blood brain and intestinal barriers that it causes transcriptional activation of gene expression both *in vitro* and *in vivo*. On the other hand, there is an increasing interest in the area of drug delivery systems by using polymers as carrier for small and large molecules. Particulate systems like polymeric nanoparticles and micelles have been applied as a physical method to improve the pharmacokinetic and pharmacodynamics profiles of the different drug molecules. It is widely that Pluronics are excellent polymer for nano-drug delivery vehicles by different routes of administration due to their wide compatibility with different drug candidates This review is aimed to highlight the Pluronics -based nanomicelles/ nanoparticles that have been developed to date.

### How to cite this article

Rahdar A, kazemi S, Askari F. Pluronic as nano-carrier platform for drug delivery systems. *Nanomed Res J*, 2018; 3(4): 174-179.

DOI: 10.22034/nmrj.2018.04.001

## INTRODUCTION

In recent years, by using nanotechnology, the nanometer-sized objects and nanomaterials were designed and fabricated that they offers the suitable tools to delivery of different drugs and other bioactive agents [1-9]. In pharmaceutical and drug delivery system (DDS), by using nanotechnology, the therapeutically active agents were formulated in various Nano form objects such as Nano particles, Nano capsules and micellar systems that demonstrated many advantages in drug delivery [3]. Among these approaches, the polymeric

micelles illustrated a remarkable potential to encapsulate poorly water-soluble drugs inward the hydrophobic core.

Emulsion is a fine dispersion of minute droplets of one liquid in another in which it is not soluble or miscible On the other hand, suspension is a mixture in which particles such as drugs are dispersed throughout the bulk of a fluid. Because of thermodynamic instability of these forms, they demonstrated phase separation upon storage. In contrast, micelles and microemulsions are stable and transparent and have lower dispersed phase size

\* Corresponding Author Email: [a.rahdar@uoz.ac.ir](mailto:a.rahdar@uoz.ac.ir)

( $\leq 200$  nm) than emulsions. Microemulsions show many advantages such as stability, transparency, low viscosity, ease of preparation and improved drug delivery systems. Furthermore, they considerably are used as drug delivery vehicle in pharmaceutical applications and treatment of diseases owing to their unique features [10]. Currently, a number of polymers conjugates that are biologically active were provided in clinical development [11]. Polyethylene glycol (PEG), poly(D,L-lactide-co-glycolide) PLGA, poly(lactic acid) (PLA), N-(2-hydroxypropyl)-methacrylate HMPA copolymers are the most copolymers that utilized for medicinal applications [12,13]. The widespread utilization of amphiphilic copolymers in the medicine and pharmaceutical applications is due to their intrinsic biological activities and properties that these properties solve problems related to drug delivery. Among various types of formulations, formulations based on pluronics have gained intense attention. Pluronic is an amphiphilic copolymers that includes a poly(propylene oxide) as hydrophobic block and poly(ethylene oxide) as a hydrophilic block. Above the critical micellar concentration (CMC), they form nanosized micellar structures. In these systems, the hydrophobic agents were encapsulated within the micellar spacious core or the hydrophilic moieties were conjugated on the surface of nanoparticles [14]. There are unique points and features associated with pluronic copolymers based delivery systems. Firstly, a number of numerous drug delivery systems which only act as simplex vehicles, poloxamers function/work as pharmacologically active polymers and modulate the response of cancerous cells [15,16]. Inasmuch pluronic are vastly classified as polymerized drugs [17]. Secondly, pluronic own tunable/flexible physicochemical properties, therefore its characteristics can be due to tunable physicochemical characteristics of pluronic copolymers, their properties can be modified and optimized. The tunable chemical properties of these polymers is considered as a unique advantage to develop the targeted delivery systems (or can caused the development of targeted delivery systems). Thirdly, pluronic based systems can be utilized for delivery of combinational therapeutic regimens more than singlet payloads. These combinational therapeutic regimens provide a platform for pharmacokinetics synchronization and pharmacodynamics synergism. Fourthly, the pluronic polymers haven't any acute-chronic toxicity and these polymers are biocompatible and safe-

to-administer agents [17,18]. Polymeric micelles illustrated several basic properties and advantages that desirable for nano-DDS [20,21]. A surrounded drug-loaded core with hydrophilic shell which provided solubilization of water insoluble drugs and also protected the incorporated agents such as protein or nucleic acid from their degradation at off-target sites. Microemulsion based formulations is one of the solubilization approaches to deal with low solubility drugs [22]. Micro emulsions have the illustrious/topping solubilization capacity for both hydrophilic and hydrophobic drugs which is contain high level of water, oil and large amount of emulsifiers (15-25%) [23]. A micro emulsion system could be formed spontaneously when fitting/suitable ratios of water, oil and a surfactant/co-surfactant are reached. Microemulsion showed several preferences for pharmaceutical use, included high solubilization capacity for hydrophilic and lipophilic drugs, thermodynamic and long-term stability, improved drug delivery and simple preparation which these advantages make the microemulsion superior to emulsion. For treatment of diseases, drugs are introduced into the body by various routes: parenteral, oral and other mucosal delivery. The oral delivery, in all of these ways, has attracted a considerable attention and become superior route as oral forms include 60% of all medical products on the market that are due to safety, wide acceptability and price [24]. Oral chemotherapy has become an important issue in medicinal field in the 21<sup>st</sup> century which may alter the prevalent issue of chemotherapy and powerfully improved the quality and condition of life of patients. Currently, for chemotherapy of the sick, the injection of anticancer drugs was used. Such a route led to great peak above the maximum tolerable concentration (MTC) of the used drug within the plasma and a limited area-under-the curve (AUC) resulted due to quick excretion of the drug from the circulate system of the body and resulting a large part of AUC would be contributed with high drug concentration above the MTC that causes the serious and important side effects. In contrast, chemotherapy by using oral route can maintain a sustained moderate concentration of the drug in the circulation system and resulting the long time exposure of cancerous cells to the drug as well as avoiding high peak above MTC.

Also, oral chemotherapy reduced prices and medicinal expenses and especially the oral chemotherapy has an overmuch importance for

cancer patients at the latest steps treatment, when sick are too weak [25-28].

#### *Pluronic as nanocarrier for drug delivery*

In the early 1960s, the emergence of lipid vesicles led to conceptual advance so that paved the way for the progress of nanomedicines. Such development caused the approval for clinical and therapeutic of a dozen of nanotechnological products. Among these, the polymeric nanoparticles attracted particular interest and attention because of their tunable properties. They utilized as drug delivery system due to their potential to navigate the drug cargo in vivo environment. As for this ability of NPs, they possess several advantages such as potential targeting and controlling the drug concentration and dispensation at the tissues, cells and sub cellular levels [29]. They also can control the drug solubility and increased the circulation time in blood compound to the corresponding naked drug and provided platform for multidrug delivery and theranostics [30]. The using of pluronic® as drug delivery system are not only recent but also, the mixture of the doxorubicin as an anticancer drug (DOX) with pluronic® L61 and F127 micelles was the first anticancer micellar system [31]. In 2013, Kabanov, researcher of supratak pharma, Inc., and co-workers reported a research that in their work mentioned to the ability of SP1049C to deplete cancerous stem cells and decreasing the tumorigenicity of cancerous cells in vivo, evolved abroad spectra of operation for SP1049C. By the encapsulation of DOX in micellar pluronic® systems, the bio distribution of DOX shifts, therefore compared to the free drug the accumulation of micellar drug in the tumors improved. The utilization of pluronic® copolymer micelle for encapsulation of anticancer drugs is the other clinical application of anticancer drugs. Docetaxel that is a semi-synthetic analog of paclitaxel, possess a potential and ability in the war against the various

solid tumors but shows disadvantages such as poorly solubility in water, fast phagocytic activity, emulgent clearance and non-election distribution. In clinical usage of docetaxel, it formulated with the non-ionic surfactant tween 80 (poly sorbate 80) which named taxotere® and the FDA approved this formulation, in 2004. However, taxotere® system illustrated serious side traces including nephrotoxicity, hypersensitivity and neurotoxicity [32]. physicochemical characteristics of some of the Pluronic® block copolymers is shown in Table 1.

In 2013 [34], a mixture of the DTX with pluronic® P105 and F127 micelles, were fabricated by Fang and co-workers that displayed a cytotoxicity toward A549-taxol resistant cancer cells more than taxotere® injections. There with, the micellar system of DTX-loaded P105/F127 demonstrated 1.58× longer blood circulation time and 3.82 × bigger areas below the plasma concentration-time curve and also in vivo therapeutic was improved. Pluronic® as surfactants, and gelation and coating agents for pharmaceutical formulation

Pluronic® tri-block copolymer are categorized as polymorph materials that depending on the molar mass ratio between the poly ethylene oxide (PEO) and poly propylene oxide (PPO) blocks can be covered arrange of gelation states from liquid to paste and solid. This versatile structure of Pluronic® are attractive due to their applications as emulsifier, solubilizing agent and dispersive ingredients for pharmaceutical formulation [35]. U.S. and British pharmacopoeias had listed the poloxamer copolymers as an excipient for variety of clinical applications [36,37]. According to the amphiphilicity and surfactant properties of poloxamer copolymers they have become suitable agent for decoration of up-conversion nanoparticles (UCNPs). UCNPs polymer coating technology led to increasing the aqueous solubility and stability of UCNPs and also provided possibility of functionalization their surface. There are

Table 1. physicochemical characteristics of some of the Pluronic® block copolymers [33].

pluronic®	Average no. of EO units (x)	Average no. of PO units (y)	Molar Mass	Cloud point 1 % Aqueous solution (°C)	HLB	CMC (M)
L61	4.55	31.03	2000	24	3	1.1 x 10 <sup>-4</sup>
L121	10.0	68.28	4400	14	1	1.0 x 10 <sup>-6</sup>
F127	200.45	65.17	12600	>100	22	2.8 x 10 <sup>-6</sup>
F68	152.73	28.97	8400	>100	29	4.8 x 10 <sup>-4</sup>
F87	122.50	39.83	7700	>100	24	9.1 x 10 <sup>-5</sup>
P105	73.88	56.03	6500	91	15	6.2 x 10 <sup>-6</sup>
P123	39.20	69.40	5750	90	8	4.4 x 10 <sup>-6</sup>

several methods for achieving stable and efficient decorations including electrostatic adsorption [38], ligand oxidation [39], ligand exchanging [40] and surface grafting [41].

Morphism of each copolymer (liquid (L), paste (P), and flake (F)) related to Pluronic® triblock copolymer has been reported in the literature [42-43].

In 2012, [44-45], the Pluronic® F127 was utilized for coating UCNPs which played role of an oil-to-water phase transfer. This oil-to-water phase transfer coating was displayed with NaYF<sub>4</sub>:Yb,Er (Tm) NPs. Using this method, a highly stable up-conversion NPs was produced that illustrated many benefits such as low general toxicity, strong luminescence characteristic and high biocompatibility. By introducing this method and according to this advantages opens new perspective for capability of UCNPs, as bio-imaging ingredients.

Hong-Ru lin and coworkers were reported a pluronic-chitosan micelles for lung delivery using lactose as excipient [46]. In this study the prepared pluronic-chitosan nanomicelles were subjected to spray-dryer to produced microencapsulated nanomicelles and used their system for lung delivery, in addition the physicochemical characterization of nanomicelles was investigated such as diameter, surface charge, morphology and stability. Due to stability of these micelles, they restore back to nanomicelles when they enter to the lung and demonstrated high stability in the lung. Also, evaluation of the in vitro drug release behavior of quercetin-loaded microencapsulated nanomicelles displayed that they have good flow ability sustained drug release behavior [46].

Doxetel (DTX) drug is one of the most important anticancer drugs that as a semi-synthetic analog of paclitaxel was used in clinical therapeutic. The DTX inhibites the microtubule depolymerization of free tubulin and has high potential in the war against a variety of solid tumors but its clinical usage is extremely hampered due to some feature of DTX such as poorly water solubility, fast phagocytic activity, renal clearance, and non-elective distribution. To overcome on these problems and improve the aqueous solubility of DTX, various drug delivery systems have been developed. Liangcen Chen and co-workers has reported a novel polymeric mixed-micelles that composed of pluronic P105 and F127 block copolymers loaded DTX against Taxol-resistant non-small cell lung cancer [46]. By using Central Composite Design, the preparation

process was optimized and drug solubility and also micelle stability improved. The in vitro cytotoxicity assay displayed that the DTX-loaded P105/F127 mixed micelles has a superior hypersensitivity effects and the mixed-micelle formulation showed a 1.85 fold longer mean residence time in blood circulation according to the in vivo pharmacokinetic study. In addition, in this system the therapeutic improvement of polymeric mixed micelles in vivo against A549/Taxol was obtained. These micelles showed tumor inhibition rate about 69.05% versus 34.43% for taxotere ( $P < 0.01$ ). The results of this investigation demonstrated that DTX-loaded P105/F127 mixed nanomicelles can use an antitumor DDS to overcome multidrug resistant in lung cancer [47].

In 2013, Bandyopadhyay and co-workers encapsulated the hydrophobic drugs including ibuprofen, aspirin and erythromycin in the hydrophobic cores of spherical pluronic F127 micelles and also, the effects of drug hydrophobicity of solution temperature and pH were investigated [47].

According to the literature [48], for all the encapsulated drugs,  $R_H$  (hydrodynamic radius) of nanomicelles decreases as a function of temperature, also at the lower temperatures the polydispersity parameter of samples subsequently increases.

The morphological features of micelles are extremely depends to the molecular architectures and hydrophobicity of their constituents. With the loading of drugs into the micelles, the radii of the micelles increases, that is in the agreement with previous experiments and reports [49-51]. At temperature  $\geq 40$ , the higher hydrophobicity of drugs ensures more compact packing of the molecules within the micellar core of pluronic. Among these drugs, aspirin, which has the least hydrophobicity, forms the largest micelles, while ibuprofen, as the most hydrophobic drug, caused the formation of the smaller and more compact micelles. In this study, a strong pH dependence on drug-encapsulated micelles was observed, with increasing of solution pH from 4.65 to 6.1, the drug molecules were ionized and led to formation of larger micelles, due to repulsive interactions within the micellar core. Subsequently, by achieving the pH=11.36 drug molecules released in the solvent.

## CONCLUSION

In summary, the conducted studies focus on polymer nanoparticles have highlighted importance and key role of different polymers

especially pluronic in drug delivery systems.

Along with the design of drug delivery systems based on new Pluronics as well as development of formulations containing Pluronic, considerable efforts have also been devoted to elaborate their role in the activity increase of the encapsulated drug.

In the current review, we have tried to present recent advances in the utilization of Pluronic® block copolymers as nano-drug delivery systems.

Reported studies confirm that there is a widespread potential to design innovative Pluronic® formulation by using various types of poloxamers to tune the biological properties according to mixed micelles. We believe that Pluronic® block copolymers will play a key role in the design of Nano drug delivery systems based on Pluronic in future.

#### CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

#### REFERENCES

1. Tong NAN, Tran NQ, Nguyen XTDT, Cao VD, Nguyen TP, Nguyen CK. Thermosensitive heparin-Pluronic® copolymer as effective dual anticancer drugs delivery system for combination cancer therapy. *International Journal of Nanotechnology*. 2018;15(12/3):174.
2. Vakilzadeh H, Varshosaz J, Minaiyan M. Pulmonary Delivery of Triptorelin Loaded in Pluronic Based Nanomicelles in Rat Model. *Current Drug Delivery*. 2018;15(5):630-40.
3. Griesser J, Hetényi G, Kadas H, Demarne F, Jannin V, Bernkop-Schnürch A. Self-emulsifying peptide drug delivery systems: How to make them highly mucus permeating. *International Journal of Pharmaceutics*. 2018;538(1-2):159-66.
4. Lai Y-H, Chiang C-S, Kao T-H, Chen S-Y. Dual-drug nanomedicine with hydrophilic F127-modified magnetic nanocarriers assembled in amphiphilic gelatin for enhanced penetration and drug delivery in deep tumor tissue. *International Journal of Nanomedicine*. 2018;Volume 13:3011-26.
5. Nguyen TTC, Nguyen CK, Nguyen TH, Tran NQ. Highly lipophilic pluronics-conjugated polyamidoamine dendrimer nanocarriers as potential delivery system for hydrophobic drugs. *Materials Science and Engineering: C*. 2017;70:992-9.
6. Maulvi FA, Desai AR, Choksi HH, Patil RJ, Ranch KM, Vyas BA, et al. Effect of surfactant chain length on drug release kinetics from microemulsion-laden contact lenses. *International Journal of Pharmaceutics*. 2017;524(1-2):193-204.
7. Cieśla J, Koczańska M, Narkiewicz-Michalek J, Szymula M, Bieganski A. Effect of  $\alpha$ -tocopherol on the properties of microemulsions stabilized by the ionic surfactants. *Journal of Molecular Liquids*. 2017;236:117-23.
8. Cieśla J, Koczańska M, Narkiewicz-Michalek J, Szymula M, Bieganski A. The physicochemical properties of CTAB solutions in the presence of  $\alpha$ -tocopherol. *Journal of Molecular Liquids*. 2016;222:463-70.
9. Cieśla J, Koczańska M, Narkiewicz-Michalek J, Szymula M, Bieganski A. Alpha-tocopherol in CTAB/NaCl systems — The light scattering studies. *Journal of Molecular Liquids*. 2017;233:15-22.
10. Dehghankelishadi P, Dorkoosh FA. Pluronic based nano-delivery systems; Prospective warrior in war against cancer. *Nanomedicine Research Journal*, 2016;1(1): 1-7.
11. Steinbach OC. Industry Update: The latest developments in therapeutic delivery. *Therapeutic Delivery*. 2013;4(7):779-84.
12. Karlsson J, Vaughan HJ, Green JJ. Biodegradable Polymeric Nanoparticles for Therapeutic Cancer Treatments. *Annual Review of Chemical and Biomolecular Engineering*. 2018;9(1):105-27.
13. Acharya S, Sahoo SK. PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. *Advanced Drug Delivery Reviews*. 2011;63(3):170-83.
14. Bae WK, Park MS, Lee JH, Hwang JE, Shim HJ, Cho SH, et al. Docetaxel-loaded thermoresponsive conjugated linoleic acid-incorporated poloxamer hydrogel for the suppression of peritoneal metastasis of gastric cancer. *Biomaterials*. 2013;34(4):1433-41.
15. Batrakova EV, Kabanov AV. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. *Journal of Controlled Release*. 2008;130(2):98-106.
16. Zhou L, Wang H, Li Y. Stimuli-Responsive Nanomedicines for Overcoming Cancer Multidrug Resistance. *Theranostics*. 2018;8(4):1059-74.
17. Li J, Yu F, Chen Y, Oupický D. Polymeric drugs: Advances in the development of pharmacologically active polymers. *Journal of Controlled Release*. 2015;219:369-82.
18. Almeida M, Magalhães M, Veiga F, Figueiras A. Poloxamers, poloxamines and polymeric micelles: Definition, structure and therapeutic applications in cancer. *Journal of Polymer Research*. 2017;25(1).
19. Danson S, Ferry D, Alakhov V, Margison J, Kerr D, Jowle D, et al. Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. *British Journal of Cancer*. 2004;90(11):2085-91.
20. Buwalda S, Al Samad A, El Jundi A, Bethry A, Bakkour Y, Coudane J, et al. Stabilization of poly(ethylene glycol)-poly( $\epsilon$ -caprolactone) star block copolymer micelles via aromatic groups for improved drug delivery properties. *Journal of Colloid and Interface Science*. 2018;514:468-78.
21. Kataoka K, Harada A, Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. *Advanced Drug Delivery Reviews*. 2001;47(1):113-31.
22. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. *Journal of Pharmacological and Toxicological Methods*. 2000;44(1):235-49.
23. Singh M. The preparation and characterization of polymeric antigen delivery systems for oral administration. *Advanced Drug Delivery Reviews*. 1998;34(2-3):285-304.
24. Florence AT, Attwood D. *Physicochemical Principles of Pharmacy*. 3 ed.1998, Palgrave: Hampshire, New York.
25. O'Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. *British Journal of Cancer*.

- 2002;87(9):933-7.
26. Feng S-S. Chemotherapeutic Engineering: Concept, Feasibility, Safety and Prospect—A Tribute to Shu Chien's 80th Birthday. *Cellular and Molecular Bioengineering*. 2011;4(4):708-16.
  27. Feng S-S, Zhao L, Tang J. Nanomedicine for oral chemotherapy. *Nanomedicine*. 2011;6(3):407-10.
  28. Feng S-S, Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. *Chemical Engineering Science*. 2003;58(18):4087-114.
  29. Barry NPE, Sadler PJ. Challenges for Metals in Medicine: How Nanotechnology May Help To Shape the Future. *ACS Nano*. 2013;7(7):5654-9.
  30. Akins RL, Lust E, Ghilzai NMK, Brown BK. Book Reviews for Vol. 68, Issue 3 ROGER G. FINCH , DAVID GREENWOOD , S. RAGNAR NORRBY , AND RICHARD J. WHITLEY .Antibiotic and Chemotherapy: Anti-Infective agents and their use in therapy, 8th ed. Edinburgh: Churchill Livingstone; 2003. 964 pp (hardcover), \$179.00. STEVEN B KAYNE AND MICHAEL H JEPSON , Editors. Veterinary Pharmacy. Chicago: Pharmaceutical Press, 2004. 606 pages (paperback), \$59.95. RAYMOND C. ROWE , PAUL J. SHESKEY , AND PAUL J. WALK .Handbook of Pharmaceutical Excipients, 4th Edition. Washington DC: American Pharmaceutical Association (APhA), 2003. xxi + 776 pp (hardcover). L. MICHAEL POSEY .Pharmacy: An Introduction to the Profession. Washington, DC: American Pharmacists Association, 2003. x + 207 pp (softcover), \$22.95. *American Journal of Pharmaceutical Education*. 2004;68(3):84.
  31. Collet JH. In Handbook of Pharmaceutical Excipients American Pharmaceutical, ed. Rowe RC, Sheskey , P, Weller PJ, American Pharmaceutical Association, Washington, DC, 2003:447–50.
  32. Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. *European Journal of Cancer*, 2001;37:1590–98.
  33. Fang X, Chen, Sha X, Jiang, Chen Y, Ren. Pluronic P105/ F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. *International Journal of Nanomedicine*. 2013:73.
  34. Ruel-Gariépy E, Leroux J-C. In situ-forming hydrogels—review of temperature-sensitive systems. *European Journal of Pharmaceutics and Biopharmaceutics*. 2004;58(2):409-26.
  35. Heron J. Mindmaps in Ophthalmology Abhishek Sharma; CRC Press, Boca Raton, FL, 2015. *Ophthalmic and Physiological Optics*. 2016;36(6):686-.
  36. Schmolka IR. Poloxamers in the Pharmaceutical Industry, CRC Press, Boca Raton FL, 1991.
  37. Pitto-Barry A, Barry NPE. Pluronic® block-copolymers in medicine: from chemical and biological versatility to rationalisation and clinical advances. *Polym Chem*. 2014;5(10):3291-7.
  38. Chen Z, Chen H, Hu H, Yu M, Li F, Zhang Q, et al. Versatile Synthesis Strategy for Carboxylic Acid–functionalized Upconverting Nanophosphors as Biological Labels. *Journal of the American Chemical Society*. 2008;130(10):3023-9.
  39. Zhou J, Yu M, Sun Y, Zhang X, Zhu X, Wu Z, et al. Fluorine-18-labeled Gd<sup>3+</sup>/Yb<sup>3+</sup>/Er<sup>3+</sup> co-doped NaYF<sub>4</sub> nanophosphors for multimodality PET/MR/UCL imaging. *Biomaterials*. 2011;32(4):1148-56.
  40. Wu Z, Guo C, Liang S, Zhang H, Wang L, Sun H, et al. A pluronic F127 coating strategy to produce stable up-conversion NaYF<sub>4</sub>:Yb,Er(Tm) nanoparticles in culture media for bioimaging. *Journal of Materials Chemistry*. 2012;22(35):18596.
  41. Kurahashi M, Kanamori K, Takeda K, Kaji H, Nakanishi K. Role of block copolymer surfactant on the pore formation in methylsilsesquioxane aerogel systems. *RSC Advances*. 2012;2(18):7166.
  42. Alexandridis P, Alan Hatton T. Poly(ethylene oxide) poly(propylene oxide) poly(ethylene oxide) block copolymer surfactants in aqueous solutions and at interfaces: thermodynamics, structure, dynamics, and modeling. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 1995;96(1-2):1-46.
  43. Ma W-D, Xu H, Wang C, Nie S-F, Pan W-S. Pluronic F127-g-poly(acrylic acid) copolymers as in situ gelling vehicle for ophthalmic drug delivery system. *International Journal of Pharmaceutics*. 2008;350(1-2):247-56.
  44. Lin H-R, Li Y-S, Lin Y-J. Novel microencapsulated Pluronic–chitosan nanomicelles for lung delivery. *Colloid and Polymer Science*. 2016;294(7):1209-16.
  45. Fang X, Chen, Sha X, Jiang, Chen Y, Ren. Pluronic P105/ F127 mixed micelles for the delivery of docetaxel against Taxol-resistant non-small cell lung cancer: optimization and in vitro, in vivo evaluation. *International Journal of Nanomedicine*. 2013:73.
  46. Basak R, Bandyopadhyay R. Encapsulation of Hydrophobic Drugs in Pluronic F127 Micelles: Effects of Drug Hydrophobicity, Solution Temperature, and pH. *Langmuir*. 2013;29(13):4350-6.
  47. Sharma PK, Bhatia SR. Effect of anti-inflammatories on Pluronic® F127: micellar assembly, gelation and partitioning. *International Journal of Pharmaceutics*. 2004;278(2):361-77.
  48. Sharma PK, Reilly MJ, Jones DN, Robinson PM, Bhatia SR. The effect of pharmaceuticals on the nanoscale structure of PEO–PPO–PEO micelles. *Colloids and Surfaces B: Biointerfaces*. 2008;61(1):53-60.
  49. Sharma PK, Reilly MJ, Jones DN, Robinson PM, Bhatia SR. The effects of anti-pharmaceuticals on the nanoscale structure of PEO-PPO-PEO micelles. *Colloids and Surfaces B: Biointerfaces*, 2008;61:53-60.
  50. Foster B, Cosgrove T, Espidel Y. PFGSE-NMR study of pH-triggered behavior in Pluronic-Ibuprofen solutions. *Langmuir*, 2009;25(12):6760.